1. 首页
  2. 产品
  3. Signaling Pathways 信号通路
  4. Metabolic Enzyme/Protease | 代谢酶/蛋白酶
  5. Endogenous Metabolite

Pharmatose DCL 14 (Pharmatose 200M; Pharmatose 450M)

别名: D-乳糖单水合物;D(+)-乳糖一水合物;一水乳糖;D-(+)-乳糖一水合物;D-(+)-Lactose Monohydrate D-(+)-乳糖一水合物;D(+)-乳糖
目录号: V70975 纯度: ≥98%
COA 产品数据 产品说明书 SDS
Pharmatose DCL 14 是一种内源性产生的代谢物。
Pharmatose DCL 14 (Pharmatose 200M; Pharmatose 450M) CAS号: 64044-51-5
产品类别: Endogenous Metabolite
产品仅用于科学研究，不针对患者销售
规格 价格 库存 数量
5g
10g
25g
50g
Other Sizes
加入购物车 结帐 大包装询价
020-31522723 sales@invivochem.cn
点击了解更多
  • 与全球5000+客户建立关系
  • 覆盖全球主要大学、医院、科研院所、生物/制药公司等
  • 产品被大量CNS顶刊文章引用
InvivoChem产品被CNS等顶刊论文引用
产品描述
Pharmatose DCL 14 是一种内源性产生的代谢物。
生物活性&实验参考方法
其他信息
α-乳糖一水合物是一种糖苷。
*注: 文献方法仅供参考, InvivoChem并未独立验证这些方法的准确性
化学信息 & 存储运输条件
分子式
C12H24O12
分子量
360.31
精确质量
360.127
CAS号
64044-51-5
PubChem CID
104938
外观&性状
White to off-white solid powder
密度
1.525
沸点
841.4ºC at 760 mmHg
熔点
433 °F (NTP, 1992) ; 201-202 °C ; Decomposes at 203.5 °C ; White powder; MP: 222.8 °C; very soluble in water; slightly soluble in ethanol; insoluble in ethyl ether, chloroform /alpha-Lactose/
闪点
462.7ºC
折射率
1.652
tPSA
198.76
氢键供体(HBD)数目
9
氢键受体(HBA)数目
12
可旋转键数目(RBC)
4
重原子数目
24
分子复杂度/Complexity
382
定义原子立体中心数目
10
SMILES
C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2O)O)O)CO)O)O)O)O.O
InChi Key
WSVLPVUVIUVCRA-KPKNDVKVSA-N
InChi Code
InChI=1S/C12H22O11.H2O/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17;/h3-20H,1-2H2;1H2/t3-,4-,5+,6+,7-,8-,9-,10-,11+,12+;/m1./s1
化学名
(2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6S)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol;hydrate
HS Tariff Code
2934.99.9001
存储方式

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month
运输条件
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
溶解度数据
溶解度 (体外实验)
H2O: 100 mg/mL (277.54 mM)
DMSO: 50 mg/mL (138.77 mM)
溶解度 (体内实验)
配方 1 中的溶解度: ≥ 2.5 mg/mL (6.94 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将100 μL 25.0 mg/mL澄清DMSO储备液加入到400 μL PEG300中，混匀；然后向上述溶液中加入50 μL Tween-80，混匀；加入450 μL生理盐水定容至1 mL。
*生理盐水的制备：将 0.9 g 氯化钠溶解在 100 mL ddH₂O中，得到澄清溶液。
配方 2 中的溶解度: ≥ 2.5 mg/mL (6.94 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将 100 μL 25.0 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中，混匀。
*20% SBE-β-CD 生理盐水溶液的制备（4°C，1 周）：将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中，得到澄清溶液。
View More

配方 3 中的溶解度: ≥ 2.5 mg/mL (6.94 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将 100 μL 25.0 mg/mL 澄清 DMSO 储备液加入到 900 μL 玉米油中并混合均匀。

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。
制备储备液 1 mg 5 mg 10 mg
1 mM 2.7754 mL 13.8769 mL 27.7539 mL
5 mM 0.5551 mL 2.7754 mL 5.5508 mL
10 mM 0.2775 mL 1.3877 mL 2.7754 mL

1、根据实验需要选择合适的溶剂配制储备液 (母液)：对于大多数产品，InvivoChem推荐用DMSO配置母液 (比如：5、10、20mM或者10、20、50 mg/mL浓度），个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;

2、如果您找不到您想要的溶解度信息，或者很难将产品溶解在溶液中，请联系我们;

3、建议使用下列计算器进行相关计算（摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等）;

4、母液配好之后，将其分装到常规用量，并储存在-20°C或-80°C，尽量减少反复冻融循环。

计算器
计算 重置

摩尔浓度计算器可计算特定溶液所需的质量、体积/浓度，具体如下：

  • 计算制备已知体积和浓度的溶液所需的化合物的质量
  • 计算将已知质量的化合物溶解到所需浓度所需的溶液体积
  • 计算特定体积中已知质量的化合物产生的溶液的浓度
使用摩尔浓度计算器计算摩尔浓度的示例如下所示：
假如化合物的分子量为350.26 g/mol，在5mL DMSO中制备10mM储备液所需的化合物的质量是多少？
  • 在分子量（MW）框中输入350.26
  • 在“浓度”框中输入10，然后选择正确的单位（mM）
  • 在“体积”框中输入5，然后选择正确的单位（mL）
  • 单击“计算”按钮
  • 答案17.513 mg出现在“质量”框中。以类似的方式，您可以计算体积和浓度。
计算 重置

稀释计算器可计算如何稀释已知浓度的储备液。例如，可以输入C1、C2和V2来计算V1，具体如下：

制备25毫升25μM溶液需要多少体积的10 mM储备溶液？
使用方程式C1V1=C2V2，其中C1=10mM，C2=25μM，V2=25 ml，V1未知：
  • 在C1框中输入10，然后选择正确的单位（mM）
  • 在C2框中输入25，然后选择正确的单位（μM）
  • 在V2框中输入25，然后选择正确的单位（mL）
  • 单击“计算”按钮
  • 答案62.5μL（0.1 ml）出现在V1框中
g/mol
计算 重置

分子量计算器可计算化合物的分子量 (摩尔质量)和元素组成，具体如下：

注：化学分子式大小写敏感：C12H18N3O4  c12h18n3o4
计算化合物摩尔质量（分子量）的说明：
  • 要计算化合物的分子量 (摩尔质量)，请输入化学/分子式，然后单击“计算”按钮。
分子质量、分子量、摩尔质量和摩尔量的定义：
  • 分子质量（或分子量）是一种物质的一个分子的质量，用统一的原子质量单位（u）表示。（1u等于碳-12中一个原子质量的1/12）
  • 摩尔质量（摩尔重量）是一摩尔物质的质量，以g/mol表示。
/
计算 重置

配液计算器可计算将特定质量的产品配成特定浓度所需的溶剂体积 (配液体积)

  • 输入试剂的质量、所需的配液浓度以及正确的单位
  • 单击“计算”按钮
  • 答案显示在体积框中
动物体内实验配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
第二步：请输入动物体内配方组成（配方适用于不溶/难溶于水的化合物），不同的产品和批次配方组成不同，如对配方有疑问，可先联系我们提供正确的体内实验配方。此外，请注意这只是一个配方计算器，而不是特定产品的确切配方。
+
+
+
计算 重置

计算结果:

工作液浓度： mg/mL；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度，请首先与我们联系。

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH2O，混匀澄清。

(1) 请确保溶液澄清之后，再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶；
            (2) 一定要按顺序加入溶剂 (助溶剂) 。

临床试验信息
Title:Testing the Capability of the Smart Underwear Device to Detect Increased Microbiome Activity Following Lactose Consumption
Status:Completed
updateDate:2026-05-01
Ctid:NCT06724705

Link: https://clinicaltrials.gov/ct2/show/NCT06724705

Conditions:Lactose Intolerance, Adult Type
Interventions:Sucrose
Phase:N/A
Title:Effect of Pharmacological Heart Rate Reduction on Visco-elastic Properties of the Arterial Wall (BRADYVASC)
Status:Completed
updateDate:2026-04-17
Ctid:NCT02584439

Link: https://clinicaltrials.gov/ct2/show/NCT02584439

Conditions:Healthy|Vascular Stiffness|Aging
Interventions:lactose capsule (placebo)
Phase:Phase 3
Title:PrEvention of Posttraumatic Joint contractuRes With Ketotifen 2
Status:Completed
updateDate:2025-12-04
Ctid:NCT03582176

Link: https://clinicaltrials.gov/ct2/show/NCT03582176

Conditions:Elbow Fracture|Elbow Injury|Elbow Dislocation
Interventions:Ketotifen Fumarate 5mg
Phase:Phase 3
View More

Title:Human Cerebral Blood Flow Regulation
Status:Completed
updateDate:2025-10-03
Ctid:NCT04265053

Link: https://clinicaltrials.gov/ct2/show/NCT04265053

Conditions:Cerebral Arterial Diseases
Interventions:Antacid
Phase:Early Phase 1
Title:Evaluating the Impact of Synbiotic Supplementation on Infants and Toddlers
Status:Active, not recruiting
updateDate:2025-09-10
Ctid:NCT06746285

Link: https://clinicaltrials.gov/ct2/show/NCT06746285

Conditions:Gastrointestinal Tolerance of Probiotics in Infants
Interventions:Lactose (inactive placebo)
Phase:N/A
Title:Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers
Status:Completed
updateDate:2024-10-31
Ctid:NCT01404754

Link: https://clinicaltrials.gov/ct2/show/NCT01404754

Conditions:Psychological Effects of Study Drug
Interventions:midomafetamine HCl
Phase:Phase 1
Title:Effect of Lactose on Blood Lipids
Status:Completed
updateDate:2024-09-23
Ctid:NCT04924530

Link: https://clinicaltrials.gov/ct2/show/NCT04924530

Conditions:Cardiovascular Risk Factor|Lipaemia|Metabolic Disease
Interventions:Lactose
Phase:N/A
Title:Lithium for Fracture Treatment: a Double Blind Randomized Controlled Trial (LiFT)
Status:Unknown status
updateDate:2024-01-26
Ctid:NCT02999022

Link: https://clinicaltrials.gov/ct2/show/NCT02999022

Conditions:Fractures
Interventions:Lactose Placebo
Phase:Phase 2
Title:Double-blind, Placebo-controlled Study of BGC20-1531 in Migraine
Status:Withdrawn
updateDate:2022-06-03
Ctid:NCT00888680

Link: https://clinicaltrials.gov/ct2/show/NCT00888680

Conditions:Migraine
Interventions:Lactose
Phase:Phase 2
Title:Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy.
Status:Completed
updateDate:2021-05-10
Ctid:NCT01041755

Link: https://clinicaltrials.gov/ct2/show/NCT01041755

Conditions:Hepatic Encephalopathy
Interventions:Lactose
Phase:Phase 4
Title:Preventing Recurrent Urinary Tract Infections With α-D-mannose
Status:Terminated
updateDate:2020-09-02
Ctid:NCT03497598

Link: https://clinicaltrials.gov/ct2/show/NCT03497598

Conditions:Urinary Tract Infections
Interventions:Lactose
Phase:Phase 4
Title:SLOS: The Effect of Simvastatin in Patients Receiving Cholesterol Supplementation
Status:Terminated
updateDate:2019-10-01
Ctid:NCT01434745

Link: https://clinicaltrials.gov/ct2/show/NCT01434745

Conditions:Smith-Lemli-Opitz Syndrome
Interventions:Lactose
Phase:N/A
Title:DAS181 Single Dose Escalation Study in Healthy Adults
Status:Completed
updateDate:2019-08-02
Ctid:NCT00876161

Link: https://clinicaltrials.gov/ct2/show/NCT00876161

Conditions:Healthy
Interventions:Lactose
Phase:Phase 1
Title:Therapeutic Lactose to Support Vaginal Microbiota
Status:Completed
updateDate:2019-03-19
Ctid:NCT03878511

Link: https://clinicaltrials.gov/ct2/show/NCT03878511

Conditions:Bacterial Vaginoses
Interventions:Placebo
Phase:N/A
Title:Allopurinol in Functional Impairment (ALFIE) Trial: 'Improving Muscle Strength'
Status:Completed
updateDate:2018-03-20
Ctid:NCT01550107

Link: https://clinicaltrials.gov/ct2/show/NCT01550107

Conditions:Sarcopenia
Interventions:Lactose tablets
Phase:Phase 4
Title:A Dietary Supplement for Early Cigarette Withdrawal
Status:Completed
updateDate:2018-02-14
Ctid:NCT02042521

Link: https://clinicaltrials.gov/ct2/show/NCT02042521

Conditions:Nicotine Dependence, Cigarettes, With Withdrawal
Interventions:Lactose Placebo
Phase:Phase 2
Title:A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen
Status:Completed
updateDate:2017-09-25
Ctid:NCT01644877

Link: https://clinicaltrials.gov/ct2/show/NCT01644877

Conditions:Parainfluenza
Interventions:Lactose Placebo
Phase:Phase 2
Title:Orall Administered Probiotics to Improve the Quality of the Vaginal Flora of Women With Breast Cancer and Chemotherapy.
Status:Completed
updateDate:2017-06-06
Ctid:NCT01723592

Link: https://clinicaltrials.gov/ct2/show/NCT01723592

Conditions:Breast Cancer
Interventions:Oral lactose placebo
Phase:N/A
Title:The Effects of N-acetylcysteine on Performance and Redox Homeostasis
Status:Completed
updateDate:2017-04-21
Ctid:NCT03121222

Link: https://clinicaltrials.gov/ct2/show/NCT03121222

Conditions:Glutathione Metabolism Anemias
Interventions:Lactose
Phase:Phase 2
Title:Evaluation of LacTEST for the Diagnosis of Hypolactasia in Adults and Elderly Patients Presenting With Clinical Symptoms of Lactose Intolerance
Status:Completed
updateDate:2016-12-28
Ctid:NCT02636413

Link: https://clinicaltrials.gov/ct2/show/NCT02636413

Conditions:Lactose Intolerance
Interventions:lactose
Phase:Phase 4
Title:Comparing the Efficacy of Pregabalin and Hydroxyzine on the Anxiety Score
Status:Completed
updateDate:2016-10-11
Ctid:NCT01675986

Link: https://clinicaltrials.gov/ct2/show/NCT01675986

Conditions:Feeling Anxious
Interventions:Lactose
Phase:Phase 2
Title:Effect of Iranian Traditional Medicine Remedy on Chemotherapy Induced Nausea and Vomiting
Status:Completed
updateDate:2016-06-03
Ctid:NCT02787707

Link: https://clinicaltrials.gov/ct2/show/NCT02787707

Conditions:Nausea|Vomiting
Interventions:lactose
Phase:Phase 2
Title:Anti-inflammatory Effect of Serum of Osteoarthritis Patients After Administration of the Oléogrape®SEED, an Extract of Grape and Olive
Status:Completed
updateDate:2016-05-20
Ctid:NCT02566798

Link: https://clinicaltrials.gov/ct2/show/NCT02566798

Conditions:Osteoarthritis
Interventions:Lactose
Phase:N/A
Title:Dextromethorphan Effect on Central Sensitization to Pain in Healthy Volunteers
Status:Completed
updateDate:2016-04-01
Ctid:NCT02596360

Link: https://clinicaltrials.gov/ct2/show/NCT02596360

Conditions:Experimental Pain|Hyperalgesia
Interventions:lactose
Phase:Phase 1
Title:The Effect of Supplementation With Species of Lactobacillus on Anthropometric Measurements
Status:Completed
updateDate:2015-05-20
Ctid:NCT02448940

Link: https://clinicaltrials.gov/ct2/show/NCT02448940

Conditions:Overweight and Obesity
Interventions:lactose
Phase:N/A
Title:Does a Perioperative Course of Gabapentin Improve Analgesia After Cesarean Delivery?
Status:Completed
updateDate:2014-10-13
Ctid:NCT01848119

Link: https://clinicaltrials.gov/ct2/show/NCT01848119

Conditions:Pain
Interventions:lactose
Phase:N/A
Title:Glucosamine Periodontal Adjunctive Therapy
Status:Terminated
updateDate:2014-08-12
Ctid:NCT02214095

Link: https://clinicaltrials.gov/ct2/show/NCT02214095

Conditions:Chronic Periodontitis
Interventions:lactose capsules
Phase:Early Phase 1
Title:Effect of Tiotropium Inhalation Capsules on Exercise Tolerance, Daily Activity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 3 Weeks of Pulmonary Rehabilitation
Status:Terminated
updateDate:2014-06-24
Ctid:NCT02172508

Link: https://clinicaltrials.gov/ct2/show/NCT02172508

Conditions:Pulmonary Disease, Chronic Obstructive
Interventions:Placebo Lactose Capsule
Phase:Phase 4
Title:Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension
Status:Terminated
updateDate:2014-03-28
Ctid:NCT00980031

Link: https://clinicaltrials.gov/ct2/show/NCT00980031

Conditions:Myocardial Remodeling
Interventions:Lactose Tablet
Phase:N/A
Title:The Effect of Statins in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status:Completed
updateDate:2014-03-24
Ctid:NCT01151306

Link: https://clinicaltrials.gov/ct2/show/NCT01151306

Conditions:Chronic Obstructive Pulmonary Disease
Interventions:Lactose tablet
Phase:Phase 4
Title:The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease
Status:Completed
updateDate:2014-01-23
Ctid:NCT01277237

Link: https://clinicaltrials.gov/ct2/show/NCT01277237

Conditions:Non Alcoholic Fatty Liver Disease
Interventions:lactose tablet
Phase:Phase 3
Title:Prophylactic Treatment of Travellers' Diarrhoea With Rifaximin
Status:Completed
updateDate:2013-11-08
Ctid:NCT00979056

Link: https://clinicaltrials.gov/ct2/show/NCT00979056

Conditions:Diarrhoea
Interventions:Lactose
Phase:Phase 3
Title:Prospective Evaluation of the Efficacy of Budesonide/Formoterol in Bronchiolitis Obliterans in AHSCT
Status:Completed
updateDate:2013-05-06
Ctid:NCT00624754

Link: https://clinicaltrials.gov/ct2/show/NCT00624754

Conditions:Obstructive Airway Disease
Interventions:lactose
Phase:Phase 2
Title:The Effects of Atorvastatin Treatment in COPD Patients
Status:Completed
updateDate:2013-04-23
Ctid:NCT01748279

Link: https://clinicaltrials.gov/ct2/show/NCT01748279

Conditions:COPD
Interventions:Lactose tablet
Phase:Phase 4
Title:Mechanism of Action of Milk and Its Components on Glycemic Control in Healthy Young Men
Status:Completed
updateDate:2013-03-18
Ctid:NCT01812967

Link: https://clinicaltrials.gov/ct2/show/NCT01812967

Conditions:Glycemic Control|Gastrointestinal Hormone Response|Healthy Young Men
Interventions:Simulated Milk Beverage
Phase:N/A
Title:The Effect of Melatonin on Nocturnal Enuresis
Status:Unknown status
updateDate:2012-11-02
Ctid:NCT01575678

Link: https://clinicaltrials.gov/ct2/show/NCT01575678

Conditions:Nocturnal Enuresis
Interventions:Lactose
Phase:Phase 2
Title:Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters
Status:Completed
updateDate:2012-06-08
Ctid:NCT01028014

Link: https://clinicaltrials.gov/ct2/show/NCT01028014

Conditions:Urethral Sphincter Activity
Interventions:Solifenacin
Phase:N/A
Title:Cholecalciferol Supplementation, Muscle Strength
Status:Completed
updateDate:2011-06-15
Ctid:NCT00682214

Link: https://clinicaltrials.gov/ct2/show/NCT00682214

Conditions:Vitamin D Deficiency
Interventions:Lactose placebo
Phase:Phase 1
Title:The Effectiveness of Gabapentin for Post-operative Pain Following Cesarean Section
Status:Completed
updateDate:2011-02-23
Ctid:NCT01094925

Link: https://clinicaltrials.gov/ct2/show/NCT01094925

Conditions:Pain
Interventions:Gabapentin 600mg
Phase:N/A
Title:Comparison of Antisecretory Effect of a Single Dose of Rabeprazole 20 mg and Omeprazole 20 mg in Obese Subjects
Status:Completed
updateDate:2010-09-24
Ctid:NCT01136317

Link: https://clinicaltrials.gov/ct2/show/NCT01136317

Conditions:Gastroesophageal Reflux
Interventions:Lactose
Phase:Phase 2
Title:Evaluation of Negative Symptoms and Cognitive Function After Administration of Antipsychotics in Healthy Volunteer
Status:Completed
updateDate:2010-08-20
Ctid:NCT01185418

Link: https://clinicaltrials.gov/ct2/show/NCT01185418

Conditions:Normal Volunteers
Interventions:lactose
Phase:
Title:Colchicine Treatment for Chronic Shoulder Pain Related to Calcific Tendonitis
Status:Unknown status
updateDate:2010-07-20
Ctid:NCT00983177

Link: https://clinicaltrials.gov/ct2/show/NCT00983177

Conditions:Calcific Tendonitis
Interventions:lactose
Phase:N/A
Title:Effects of Lactose on Fecal Microflora
Status:Completed
updateDate:2009-09-21
Ctid:NCT00599859

Link: https://clinicaltrials.gov/ct2/show/NCT00599859

Conditions:Lactose Intolerance
Interventions:lactose
Phase:N/A
Title:Deanxit and Rivotril in Tinnitus Patients
Status:Completed
updateDate:2009-08-11
Ctid:NCT00841230

Link: https://clinicaltrials.gov/ct2/show/NCT00841230

Conditions:Tinnitus
Interventions:Lactose placebo
Phase:Phase 4
Title:St. John's Wort in the Treatment of Raynaud's Phenomenon
Status:Completed
updateDate:2009-07-14
Ctid:NCT00351117

Link: https://clinicaltrials.gov/ct2/show/NCT00351117

Conditions:Raynaud's Disease
Interventions:Lactose
Phase:Phase 3
Title:Pharmacological Modulations of Allergen-Specific Immunotherapy
Status:Completed
updateDate:2008-04-11
Ctid:NCT00504946

Link: https://clinicaltrials.gov/ct2/show/NCT00504946

Conditions:Asthma
Interventions:lactose
Phase:Phase 3
Title:Melatonin Treatment and Inflammation, Oxidative Stress and Autonomic Function in Connection With Surgery
Status:Unknown status
updateDate:2006-04-05
Ctid:NCT00311259

Link: https://clinicaltrials.gov/ct2/show/NCT00311259

Conditions:Oxidative Stress|Inflammatory Stress|Myocardial Ischaemia
Interventions:Laktose
Phase:

相关产品
  • L-Histidinol-d3
  • D-myo-Inositol-3-phosphate sodium
    V120372 1g
    D-inositol-3-phosphate sodium is a member of the inositol phosphate second messenger family and plays an important role in cell signaling.
    Get Quote
  • (±)19(20)-DiHDPA
    V120345 1350373-35-1 1g
    When docosahexaenoic acid (DHA) was incubated with rat liver microsomes supplemented with NADPH, (±)19(20)-DiHDPA was one of the major metabolites produced.
    Get Quote
  • 4-Hydroxy-2-butanone
    V120398 590-90-9 1g
    Get Quote
联系我们
电话: 020-31522723 传真: 463611831 邮箱: sales@invivochem.cn
获得最新产品资讯、折扣和优惠
姓名
邮箱

InvivoChem的所有产品仅用于作科学研究，不面向患者销售

Copyright 2020 InvivoChem LLC | All Rights Reserved 粤ICP备20063088号-1

 粤公网安备 44011102003439号

联系我们
Home Classify Cart Member